Call Us: 1.800.873.5297


Update of FDA’s Treatment of Acetaminophen

Beginning yesterday, the FDA gathered more than 35 experts in Maryland to discuss their options of how to prevent overdoses of over-the-counter acetaminophen. Acetaminophen is the pain and fever reducing active ingredient in drugs such as Tylenol and Excedrin. Acetaminophen overdose is the leading cause of liver failure in the United States. We reported in […]


Doctor Admits Giving Patients the Wrong Radiation Doses

A Philadelphia doctor, who has been accused of botching dozens of prostate cancer surgeries at a Veterans Administration hospital, admitted Monday that he sometimes missed his target when implanting radioactive seeds, leaving patients with incorrect dosages.Dr. Gary Kao said these mistakes are commonplace when you are aiming seeds at the walnut-sized prostate, which sits near […]


New Cancer Drug Has Been Very Effective in Animal Trials

A new method of attacking cancer cells, developed by researchers in Australia, has proved surprisingly effective in animal tests.The method is intended to sidestep two major drawbacks of standard chemotherapy: the treatment’s lack of specificity and the fact that cancer cells often develop resistance to treatment. The new method, called EnGeneIC, uses “minicells” to deliver […]


Accutane Pulled Off the Market after Jury Verdict

Roche Holding AG, one of biggest makers of cancer drugs, pulled its Accutane acne medicine from the U.S. market after juries awarded at least $33 million in damages to users who blamed the drug for bowel disease. Roche notified the FDA today that it would be withdrawing Accutane after a reevaluation of the product showed […]


CDC to Reinstate Booster Shots for Babies and Toddlers

The U.S. Center for Disease Control and Prevention (CDC) announced today that it plans to reinstate booster shots of the vaccine HiB (Haemphilus influenza type b) for babies and toddlers ages 12 to 15 months. The vaccine protects against bacterial meningitis. In 2007, Merck & Co. Inc. recalled its HiB vaccines due to the fact […]


Piroxicam Label in Canada to be Revised

On June 25, 2009, Health Canada, an organization similar to the FDA, announced new restrictions fro Piroxicam. The agency concluded that piroxicam should no longer be used to treat short-term pain and inflammation because of an increased risk of serious skin reactions and gastrointestinal problems relative to other similar drugs. Piroxicam is a prescription drug […]


Clot-Blocking Drug for Stroke Patients Advised Can be Used for Longer Period of Time than Originally Thought

The American Heart Association (AHA) released an advisory that a “clot-busting” drug can be effective for an extra 90 minutes longer than what the FDA has approved the drug for. The drug, called recombinant-tissue plasminogen activator, or rt-PA, is one that can be administered to stroke patients when they enter the hospital and will immediately […]


FDA Approves Generic Version of Plan B Emergency Contraceptive

Today the FDA approved the first generic version of Plan B, an emergency contraceptive tablet that contains 0.75 mg of Levonorgestrel. The generic product will only be available by prescription for women ages 17 and under. Plan B, which is manufactured by Duramed Pharmaceuticals Inc., was first approved in 1999. Women of all ages were […]


600 Neighborhoods Have Elevated Cancer Risks

According to new data released by the Environmental Protection Agency (EPA), people living in nearly 600 neighborhoods across the country are breathing concentrations of toxic air pollutions that put them at a much greater risk of contracting cancer. The levels of 80 cancer-causing substances released by automobiles, factories, and other sources, in these neighborhoods produce […]


Faulty Insurance Database Overcharged Patients for Healthcare

This week congressional investigators announced that two-thirds of the health insurance industry used a faulty database, which in turned cost patients when seeing doctors outside of the insurance network billions in inflated bills. The database operated by Ingenix, a subsidiary of UnitedHealth Group, agreed in January to pay $350 million to settle allegations that i […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.